Fundamental Analysis of XOMA CORP(NASDAQ:XOMA) stock

Fundamental Rating

Overall XOMA gets a fundamental rating of 2 out of 10. We evaluated XOMA against 588 industry peers in the Biotechnology industry. XOMA may be in some trouble as it scores bad on both profitability and health. XOMA is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year XOMA has reported negative net income.

XOMA had a negative operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: XOMA reported negative net income in multiple years.

In multiple years XOMA reported negative operating cash flow during the last 5 years.

1.2 Ratios

With an excellent Return On Assets value of -19.76%, XOMA belongs to the best of the industry, outperforming 82.59% of the companies in the same industry.

XOMA has a better Return On Equity (-52.19%) than 66.55% of its industry peers.

		Industry Rank	Sector Rank
ROA	-19.76%
ROE	-52.19%
ROIC	N/A

ROA(3y)-10.35%

ROA(5y)-5.19%

ROE(3y)-21.59%

ROE(5y)-11.77%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

XOMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

XOMA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for XOMA remains at a similar level compared to 1 year ago.

Compared to 5 years ago, XOMA has more shares outstanding

XOMA has a worse debt/assets ratio than last year.

2.2 Solvency

XOMA has an Altman-Z score of -5.67. This is a bad value and indicates that XOMA is not financially healthy and even has some risk of bankruptcy.

XOMA's Altman-Z score of -5.67 is on the low side compared to the rest of the industry. XOMA is outperformed by 64.68% of its industry peers.

XOMA has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.

The Debt to Equity ratio of XOMA (1.34) is worse than 80.38% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.34
Debt/FCF	N/A
Altman-Z	-5.67

ROIC/WACCN/A

WACC8.36%

2.3 Liquidity

A Current Ratio of 8.68 indicates that XOMA has no problem at all paying its short term obligations.

XOMA's Current ratio of 8.68 is fine compared to the rest of the industry. XOMA outperforms 75.77% of its industry peers.

A Quick Ratio of 8.68 indicates that XOMA has no problem at all paying its short term obligations.

XOMA has a Quick ratio of 8.68. This is in the better half of the industry: XOMA outperforms 75.77% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.68
Quick Ratio	8.68

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for XOMA have decreased strongly by -10.20% in the last year.

XOMA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.01%.

The Revenue has been decreasing by -2.13% on average over the past years.

EPS 1Y (TTM)-10.2%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q22.22%

Revenue 1Y (TTM)-21.01%

Revenue growth 3Y-45.5%

Revenue growth 5Y-2.13%

Revenue growth Q2Q23.02%

3.2 Future

Based on estimates for the next years, XOMA will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.00% on average per year.

XOMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 67.69% yearly.

EPS Next Y-1.06%

EPS Next 2Y9.31%

EPS Next 3Y16%

EPS Next 5YN/A

Revenue Next Year116.92%

Revenue Next 2Y78.24%

Revenue Next 3Y67.69%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

XOMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year XOMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as XOMA's earnings are expected to grow with 16.00% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y9.31%

EPS Next 3Y16%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for XOMA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

XOMA CORP

NASDAQ:XOMA (5/1/2024, 3:01:47 PM)

After market: 25.82 0 (0%)

25.82

+0.48 (+1.89%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap300.54M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-19.76%
ROE	-52.19%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	1.34
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	8.68
Quick Ratio	8.68
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-10.2%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-1.06%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-21.01%

Revenue growth 3Y-45.5%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

XOMA CORP (XOMA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens